Post Marketing Survey of Clozapine in treatment-resistant schizophrenia patients in Japan -sub analyses by patients&apos; background factors-

Kazuhiro TORIYAMA

4:48 PM - 4:56 PM

[CNP-P14-2] Post Marketing Survey of Clozapine in treatment-resistant schizophrenia patients in Japan -sub analyses by patients' background factors-

^○Kazuhiro TORIYAMA¹, Tomomi MIKAMI², Yoshihisa SATOU³, Takayoshi SASAJIMA² (1. Medical division, Novartis Pharma K.K., Tokyo Japan, 2. Japan Development, Novartis Pharma K.K., Tokyo Japan, 3. Regulatory Office, Novartis Pharma K.K., Tokyo Japan)

Abstract password authentication.
Password to browse/download the abstracts has been sent to pre-registrants by email and printed on name badge. It is also indicated in the abstract booklet.

Presentation information

[CNP_P14] Poster Session 14

[CNP-P14-2] Post Marketing Survey of Clozapine in treatment-resistant schizophrenia patients in Japan -sub analyses by patients' background factors-

Password